STOCK TITAN
  1. Home
  2. Sec-filings
  3. LXRX
  4. [Form 4] LEXICON PHARMACEUTICALS, INC. Insider Trading Activity

Executive at Lexicon (NASDAQ: LXRX) settles tax via share withholding

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LEXICON PHARMACEUTICALS, INC. senior vice president Lisa DeFrancesco reported equity award activity on common stock. On February 28, 2026, she acquired shares through the exercise and conversion of restricted stock units, including 24,674 and 128,190 units, each representing a right to one common share. A separate transaction disposed of 74,572 common shares at $1.47 per share to satisfy tax withholding obligations, leaving her with directly owned common shares as reported in the filing.

Positive

  • None.

Negative

  • None.
Insider DeFrancesco Lisa
Role SVP, IR and Corp Comm
Type Security Shares Price Value
Exercise Restricted Stock Units 24,674 $0.00 $0.00
Exercise Restricted Stock Units 128,190 $0.00 $0.00
Exercise Common Stock 24,674 $0.00 $0.00
Exercise Common Stock 128,190 $0.00 $0.00
Exercise Price or Tax Liability Common Stock 74,572 $1.47 $110K
Holdings After Transaction: Restricted Stock Units — 281,053 shares (Direct); Common Stock — 93,869 shares (Direct)
Footnotes (4)
  1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
  2. F2. Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
  3. F3. Each restricted stock unit represents a contingent right to receive one share of common stock.
  4. F4. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did Lexicon Pharmaceuticals (LXRX) report for Lisa DeFrancesco?
Lisa DeFrancesco reported equity award activity involving restricted stock units and common stock. She exercised and converted restricted stock units into common shares, and a portion of those shares was withheld by the company to cover tax obligations, as reflected in the Form 4 filing details.

How many restricted stock units did Lisa DeFrancesco convert at Lexicon Pharmaceuticals (LXRX)?
Lisa DeFrancesco converted 24,674 and 128,190 restricted stock units into common stock. Each restricted stock unit represents a contingent right to receive one share of Lexicon common stock, according to the filing footnotes describing the structure of these equity awards and their settlement terms.

How do restricted stock units work in this Lexicon Pharmaceuticals (LXRX) Form 4?
Each restricted stock unit grants a contingent right to receive one common share. The footnotes state these units vest in thirds on February 28 of each of the three years following the year of grant, and then settle in common stock upon vesting and conversion.

What vesting schedule applies to Lisa DeFrancesco’s restricted stock units at Lexicon Pharmaceuticals (LXRX)?
The restricted stock units vest in three equal installments. One-third of the shares vest on February 28 of each of the three years following the year in which the grant was made, as outlined in the footnote describing the RSU vesting terms in the Form 4.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DeFrancesco Lisa
(Last) (First) (Middle)
2445 TECHNOLOGY FOREST BLVD
11TH FLOOR
(Street)
SPRING TX 77381
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, IR and Corp Comm
3. Date of Earliest Transaction (Month/Day/Year)
02/28/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/28/2026 M 24,674 A (1) 40,251 D
Common Stock 02/28/2026 M 128,190 A (1) 168,441 D
Common Stock 02/28/2026 F(2) 74,572 D $1.47 93,869 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (3) 02/28/2026 M 24,674 (4) (4) Common Stock 24,674 (1) 24,673 D
Restricted Stock Units (1) 02/28/2026 M 128,190 (4) (4) Common Stock 128,190 (1) 256,380 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of common stock.
2. Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
3. Each restricted stock unit represents a contingent right to receive one share of common stock.
4. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
/s/ Lisa M. DeFrancesco 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR